Bessemer Group
IMNM icon

Bessemer Group’s Immunome IMNM Stock Holding History

Bessemer Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,388
Closed -$20K – 2555
2024
Q3 		$20K Buy
1,388
+530
+62% +$7.53K ﹤0.01% 1494
2024
Q2 		$10K Hold
858
– – ﹤0.01% 1525
2024
Q1 		$21K Buy
+858
New +$17.4K ﹤0.01% 1418

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's IMNM Position: Q4 2024 in Review

Bessemer Group sold out of Immunome (IMNM) in Q4 2024, closing a stake of 1,388 shares — an estimated $20K sold.

Bessemer Group first reported a position in IMNM in Q1 2024 and held it in 3 quarters. The position peaked at $21K in Q1 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

  • Bessemer Group reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
  • Bessemer Group sold 1,388 Immunome shares in Q4 2024, an estimated $20K.
  • Bessemer Group first reported a position in Immunome in Q1 2024 and held it in 3 quarters.
  • Bessemer Group's Immunome position peaked at $21K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.